Best Stocks Under $2 Right Now It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $2.00 (2 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. OverviewStocks Under $0.05Stocks Under $0.10Stocks Under $0.25Stocks Under $0.50Stocks Under $1Stocks Under $2Stocks Under $3Stocks Under $5Stocks Under $10Stocks Under $20Stocks Under $30Stocks Under $50Stocks On Sale 1. OS Therapies NYSE:OSTX$1.59 0.00 (0.00%) As of 05/20/2025 04:00 PM EasternOS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. More about OS TherapiesMarket Capitalization$34.45 millionP/E Ratio-1.85Consensus RatingBuyConsensus Price Target$18.00 (+1,032.1% Upside)Volume328,801 sharesAverage Volume478,344 shares Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. 2. Denison Mines NYSEAMERICAN:DNN$1.45 +0.04 (+2.84%) As of 05/20/2025 04:10 PM EasternDenison Mines Corp. engages in the acquisition, exploration, and development of uranium bearing properties in Canada. Its flagship project is the Wheeler River uranium project covering an area of approximately 300,000 hectares located in the Athabasca Basin region in northern Saskatchewan. More about Denison MinesMarket Capitalization$1.30 billionP/E Ratio-145.00Consensus RatingBuyConsensus Price Target$3.00 (+106.9% Upside)Volume58.95 million sharesAverage Volume32.37 million shares3. Quince Therapeutics NASDAQ:QNCX$1.02 +0.07 (+7.45%) As of 05/20/2025 04:00 PM EasternQuince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. More about Quince TherapeuticsMarket Capitalization$43.16 millionP/E Ratio-0.82Consensus RatingBuyConsensus Price Target$8.00 (+684.3% Upside)Volume349,443 sharesAverage Volume286,601 shares4. Cardiol Therapeutics NASDAQ:CRDL$1.12 0.00 (0.00%) As of 05/20/2025 04:00 PM EasternCardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. More about Cardiol TherapeuticsMarket Capitalization$92.52 millionP/E Ratio-2.87Consensus RatingBuyConsensus Price Target$8.40 (+650.0% Upside)Volume117,508 sharesAverage Volume365,242 shares5. GeoVax Labs NASDAQ:GOVX$1.04 +0.02 (+1.96%) As of 05/20/2025 04:00 PM EasternGeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. More about GeoVax LabsMarket Capitalization$15.80 millionP/E Ratio-0.28Consensus RatingBuyConsensus Price Target$11.10 (+967.3% Upside)Volume272,974 sharesAverage Volume538,418 shares6. Reviva Pharmaceuticals NASDAQ:RVPH$1.04 +0.15 (+16.85%) As of 05/20/2025 04:00 PM EasternReviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. More about Reviva PharmaceuticalsMarket Capitalization$48.61 millionP/E Ratio-0.94Consensus RatingBuyConsensus Price Target$9.00 (+765.4% Upside)Volume691,327 sharesAverage Volume1.14 million shares7. Immunic NASDAQ:IMUX$0.97 +0.01 (+1.34%) As of 05/20/2025 04:00 PM EasternImmunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. More about ImmunicMarket Capitalization$93.29 millionP/E Ratio-0.79Consensus RatingBuyConsensus Price Target$13.20 (+1,255.8% Upside)Volume394,652 sharesAverage Volume715,245 shares8. Western Copper & Gold NYSE:WRN$1.14 +0.08 (+7.55%) As of 05/20/2025 04:00 PM EasternWestern Copper & Gold Corp. operates as an exploration stage company, which engages in the acquisition, exploration, and future development of mineral resource properties. More about Western Copper & GoldMarket Capitalization$228 millionP/E Ratio-57.00Consensus RatingBuyConsensus Price Target$4.25 (+272.8% Upside)Volume751,754 sharesAverage Volume366,669 shares9. Ur-Energy NYSEAMERICAN:URG$0.70 +0.02 (+2.83%) As of 05/20/2025 04:10 PM EasternUr-Energy Inc engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. More about Ur-EnergyMarket Capitalization$256.62 millionP/E Ratio-5.42Consensus RatingBuyConsensus Price Target$2.30 (+226.3% Upside)Volume2.41 million sharesAverage Volume4.14 million shares10. Stardust Power NASDAQ:SDST$0.61 +0.05 (+9.67%) As of 05/20/2025 04:00 PM EasternStardust Power Inc is a vertically-integrated lithium refinery that engages in producing battery-grade lithium. The company was founded in 2022 and is based in Greenwich, Connecticut.Market Capitalization$35.13 millionP/E Ratio-0.82Consensus RatingBuyConsensus Price Target$5.11 (+742.7% Upside)Volume755,179 sharesAverage Volume404,579 shares11. Context Therapeutics NASDAQ:CNTX$0.68 -0.03 (-3.89%) As of 05/20/2025 04:00 PM EasternContext Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. More about Context TherapeuticsMarket Capitalization$60.89 millionP/E Ratio-0.75Consensus RatingBuyConsensus Price Target$6.00 (+783.9% Upside)Volume177,934 sharesAverage Volume286,175 shares12. Rani Therapeutics NASDAQ:RANI$0.75 +0.05 (+7.01%) As of 05/20/2025 04:00 PM EasternRani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. More about Rani TherapeuticsMarket Capitalization$40.24 millionP/E Ratio-0.71Consensus RatingBuyConsensus Price Target$9.40 (+1,154.8% Upside)Volume407,052 sharesAverage Volume797,445 shares13. FibroBiologics NASDAQ:FBLG$0.91 +0.00 (+0.27%) As of 05/20/2025 04:00 PM EasternFibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. More about FibroBiologicsMarket Capitalization$34.95 millionP/E Ratio-4.35Consensus RatingBuyConsensus Price Target$13.00 (+1,323.3% Upside)Volume123,025 sharesAverage Volume298,541 shares14. Lucid Diagnostics NASDAQ:LUCD$1.30 +0.04 (+3.17%) As of 05/20/2025 04:00 PM EasternLucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. More about Lucid DiagnosticsMarket Capitalization$140.65 millionP/E Ratio-1.14Consensus RatingBuyConsensus Price Target$3.50 (+169.2% Upside)Volume1.04 million sharesAverage Volume504,186 shares15. Gain Therapeutics NASDAQ:GANX$1.91 -0.05 (-2.55%) As of 05/20/2025 04:00 PM EasternGain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. More about Gain TherapeuticsMarket Capitalization$56.46 millionP/E Ratio-1.74Consensus RatingBuyConsensus Price Target$8.20 (+329.3% Upside)Volume173,323 sharesAverage Volume309,681 shares16. ProQR Therapeutics NASDAQ:PRQR$1.76 +0.05 (+2.92%) As of 05/20/2025 04:00 PM EasternProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. More about ProQR TherapeuticsMarket Capitalization$185.18 millionP/E Ratio-5.50Consensus RatingBuyConsensus Price Target$8.00 (+354.5% Upside)Volume394,440 sharesAverage Volume626,465 shares17. Nkarta NASDAQ:NKTX$1.80 +0.10 (+5.88%) As of 05/20/2025 04:00 PM EasternNkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. More about NkartaMarket Capitalization$127.72 millionP/E Ratio-0.96Consensus RatingBuyConsensus Price Target$14.67 (+714.8% Upside)Volume458,647 sharesAverage Volume1.07 million shares18. Aclaris Therapeutics NASDAQ:ACRS$1.35 +0.05 (+3.85%) As of 05/20/2025 04:00 PM EasternAclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. More about Aclaris TherapeuticsMarket Capitalization$146.18 millionP/E Ratio-2.60Consensus RatingBuyConsensus Price Target$10.00 (+640.7% Upside)Volume487,036 sharesAverage Volume1.18 million shares19. Zura Bio NASDAQ:ZURA$1.07 -0.01 (-0.93%) As of 05/20/2025 04:00 PM EasternZura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. More about Zura BioMarket Capitalization$73.16 millionP/E Ratio-1.53Consensus RatingBuyConsensus Price Target$14.33 (+1,239.6% Upside)Volume605,610 sharesAverage Volume403,307 shares20. Biomea Fusion NASDAQ:BMEA$1.57 +0.06 (+3.97%) As of 05/20/2025 04:00 PM EasternBiomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. More about Biomea FusionMarket Capitalization$58.99 millionP/E Ratio-0.39Consensus RatingBuyConsensus Price Target$22.60 (+1,339.5% Upside)Volume617,458 sharesAverage Volume910,541 shares21. Autolus Therapeutics NASDAQ:AUTL$1.53 +0.05 (+3.38%) As of 05/20/2025 04:00 PM EasternAutolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. More about Autolus TherapeuticsMarket Capitalization$407.20 millionP/E Ratio-1.26Consensus RatingBuyConsensus Price Target$9.32 (+509.2% Upside)Volume2.43 million sharesAverage Volume1.48 million shares22. SAB Biotherapeutics NASDAQ:SABS$1.84 +0.04 (+2.37%) As of 05/20/2025 02:58 PM EasternSAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. More about SAB BiotherapeuticsMarket Capitalization$17.12 millionP/E Ratio-0.50Consensus RatingBuyConsensus Price Target$12.20 (+562.1% Upside)Volume17,537 sharesAverage Volume65,681 shares23. Cabaletta Bio NASDAQ:CABA$1.88 -0.04 (-2.08%) As of 05/20/2025 04:00 PM EasternCabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. More about Cabaletta BioMarket Capitalization$95.40 millionP/E Ratio-0.87Consensus RatingBuyConsensus Price Target$20.33 (+981.6% Upside)Volume2.15 million sharesAverage Volume1.55 million shares24. Skye Bioscience NASDAQ:SKYE$1.97 +0.24 (+13.87%) As of 05/20/2025 02:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Skye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. More about Skye BioscienceMarket Capitalization$62.26 millionP/E Ratio-2.52Consensus RatingBuyConsensus Price Target$16.60 (+746.1% Upside)Volume320,782 sharesAverage Volume362,407 shares25. Skye Bioscience NASDAQ:SKYE$1.97 -0.18 (-8.37%) As of 05/20/2025 04:00 PM EasternSkye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. More about Skye BioscienceMarket Capitalization$61.02 millionP/E Ratio-2.40Consensus RatingBuyConsensus Price Target$16.60 (+742.6% Upside)Volume260,900 sharesAverage Volume362,407 shares More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Viking Holdings Posts Strong Q1, Eyes Growth Ahead 2 Reasons Netflix’s 40% Rally Is Far From Over Hims & Hers Stock Chart Points to Strong Bullish Continuation Boeing Landed New Deals With China and the Saudis for More Upside CrowdStrike’s Rally Faces a Test—Here’s Why That’s Good NVIDIA-Backed CoreWeave Jumps 28%: Is It The Next Great AI Buy? UnitedHealth Insiders Double Down: Is UNH Stock a Value Play? Walmart Stock Holds as Tariff Risk Spurs Support Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
